NEW

Switch to Dark

Pricing

Learn

DXCM - Dexcom Inc

132

$67.27

-$0.39 (-0.576%)

At market close

$67.28

$0.01 (0.019%)

After Hours 3/19/26, 8:02 PM

4.33/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

DXCM

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$26.10B

Industry

Health Care

EPS (TTM)

$2.09

P/E (TTM)

31.21

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

5.60

P/B

9.51

Diluted Shares

398.90M

Ex-Dividend

--

Next Earnings

04-29

Forward P/E

26.63

Payout Ratio

--

P/FCF (TTM)

24.23

FCF Yield

4.13%

Earnings Yield

3.20%

52 Week Range

Score Card

Explore Scores Tab

4.33

Very Good

Dexcom Inc has grown revenue at 15.6% over the past year, which is strong growth. Also, it has seen its diluted average shares outstanding decrease by -1.92% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

3.00

Average

Management

2.00

Bad

Growth

2.00

Bad

Profitability

4.00

Good

Fin. Health

4.00

Good

Dividends

--

--

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-18 16:07:04

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-16 16:02:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:02:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:01:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:01:50

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:01:43

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:01:36

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:01:31

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-02 16:15:56

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 16:32:14

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-02-26 16:30:15

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-02-26 16:15:59

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$117.60

74.8%

Avg:

$88.34

31.3%

Low:

$68.68

2.1%

(% change is relative to the current stock price: $67.27)

Analyst Recommendations

Go to Analyst Tab

4.22

Very Good

41%

Strong Buy (15)

43%

Buy (16)

14%

Hold (5)

3%

Sell (1)

0%

Strong Sell (0)

About

Website
https://www.dexcom.com/
Address
6340 Sequence Drive, San Diego CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1093557

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

IPO Date

2005-04-14

Industry

Health Care

Total Employees

11,000

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services